Overview

This trial is active, not recruiting.

Conditions traumatic spinal cord injury, neuropathic pain
Treatment blood samples
Sponsor The University of Texas Health Science Center, Houston
Collaborator The Institute for Rehabilitaion and Research Foundation
Start date June 2009
End date June 2020
Trial size 120 participants
Trial identifier NCT00913471, HSC-MS-07-0452

Summary

The investigators propose to compare plasma protein profiles for SCI patients with/without chronic neuropathic pain in order identify biomarker(s) that are associated with this medical condition. Secondly, the investigators propose to identify a temporal relationship to initial SCI at which these biomarkers manifest.

Our working hypothesis is that sustained alterations in specific inflammatory molecules are associated with chronic neuropathic pain following SCI, and that their plasma levels can serve as biomarkers to identify patients at risk for the development of neuropathic pain.

Additionally the investigators are collecting skin tissue biopsy samples from patients following acute and chronic spinal cord injury to create vector-free human iPS cells from fibroblasts by direct delivery of reprogramming proteins.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
blood samples
Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample. Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample. Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.
blood samples
Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample. Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample. Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.
blood samples
Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample. Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample. Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.

Primary Outcomes

Measure
To identify candidate biomarkers for pain in the chronic SCI samples.
time frame: two or more years post injury

Secondary Outcomes

Measure
To identify the temporal relationship of the development of pain and the manifestation of the biomarkers identified
time frame: two or more years post injury

Eligibility Criteria

Male or female participants from 18 years up to 90 years old.

A. Chronic Patients Inclusion: 1. Two or more years post traumatic SCI with deficit Exclusion: 1. < 18 years of age 2. Evidence of brain injury on computed tomography (CT) (SCI patients need to be able to comply with completing the pain survey) 3. Other medical condition that accounts for chronic pain (i.e. diabetic neuropathy, renal insufficiency, multiple sclerosis, HIV associated neuropathy, alcohol-related neuropathy) 4. Temperature > 100.5°C 5. History of infection within the last 30 days (i.e. UTI, URI, pressure sore) 6. History of Pulmonary Embolus (PE) or deep vein thrombosis (DVT) 7. Inability to obtain informed consent 8. Psychiatric problems (patients need to be able to complete the pain survey) 9. Diagnosis or treatment of cancer in the last 5 years B. Longitudinal, Prospective Cohort Patients: Inclusion: 1. Initial traumatic SCI with deficit Exclusion: Same as listed above C. Healthy Volunteers Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have, 1. No significant medical history (pain free) 2. No recent infections 3. Take no medications 4. Fever free 5. Greater than 18 years old

Additional Information

Official title Biomarkers for Pain in Spinal Cord Injury (SCI) Patients
Principal investigator Georgene Hergenroeder, MHA, RN
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by The University of Texas Health Science Center, Houston.